The stock of Mereo Biopharma Group Plc ADR (MREO) has gone up by 5.28% for the week, with a -7.43% drop in the past month and a -15.47% drop in the past quarter. The volatility ratio for the week is 3.72%, and the volatility levels for the past 30 days are 6.14% for MREO. The simple moving average for the past 20 days is 2.87% for MREO’s stock, with a 1.49% simple moving average for the past 200 days.
Is It Worth Investing in Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Right Now?
The stock has a 36-month beta value of 0.91. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MREO is 137.28M, and at present, short sellers hold a 4.10% of that float. On December 06, 2024, the average trading volume of MREO was 757.85K shares.
MREO) stock’s latest price update
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) has experienced a rise in its stock price by 9.38 compared to its previous closing price of 3.47. However, the company has seen a gain of 5.28% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-26 that Mereo BioPharma Group plc’s setrusumab shows promise in treating osteogenesis imperfecta, with phase 3 studies fully enrolled and potential for multiple catalysts in 2025. Positive 14-month data from the phase 2/3 ORBIT study indicates a significant reduction in fracture rates, bolstering confidence in ongoing phase 3 trials. Financially stable with $87.4 million in cash, Mereo aims to secure a partner for Alvelestat’s phase 3 trial, potentially boosting stock value.
Analysts’ Opinion of MREO
Robert W. Baird, on the other hand, stated in their research note that they expect to see MREO reach a price target of $8. The rating they have provided for MREO stocks is “Outperform” according to the report published on June 13th, 2024.
BTIG Research gave a rating of “Buy” to MREO, setting the target price at $4 in the report published on October 13th of the previous year.
MREO Trading at -6.15% from the 50-Day Moving Average
After a stumble in the market that brought MREO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.39% of loss for the given period.
Volatility was left at 6.14%, however, over the last 30 days, the volatility rate increased by 3.72%, as shares sank -6.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.20% lower at present.
During the last 5 trading sessions, MREO rose by +5.55%, in comparison to the 20-day moving average, which settled at $3.69. In addition, Mereo Biopharma Group Plc ADR saw 64.31% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MREO starting from Scots-Knight Denise, who sale 60,046 shares at the price of $4.22 back on Sep 13 ’24. After this action, Scots-Knight Denise now owns 808,921 shares of Mereo Biopharma Group Plc ADR, valued at $253,454 using the latest closing price.
Scots-Knight Denise, the Chief Executive Officer of Mereo Biopharma Group Plc ADR, sale 28,611 shares at $4.47 during a trade that took place back on Sep 12 ’24, which means that Scots-Knight Denise is holding 868,967 shares at $127,968 based on the most recent closing price.
Stock Fundamentals for MREO
Current profitability levels for the company are sitting at:
- -104.62 for the present operating margin
- -1.07 for the gross margin
The net margin for Mereo Biopharma Group Plc ADR stands at -117.01. The total capital return value is set at -0.51.
Based on Mereo Biopharma Group Plc ADR (MREO), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -22.6. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -38.01.
Currently, EBITDA for the company is -26.06 million with net debt to EBITDA at 2.13. When we switch over and look at the enterprise to sales, we see a ratio of 1393.47. The receivables turnover for the company is 0.13for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.10.
Conclusion
To sum up, Mereo Biopharma Group Plc ADR (MREO) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
